Featured Article

Effect on Hemoglobin A1c HbA1c and Body Weight After Discontinuation - whimsical transformation

Heather Aug 05, 2026

PDF Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation ...

Effect on Hemoglobin A1c HbA1c and Body Weight After Discontinuation
Effect on Hemoglobin A1c HbA1c and Body Weight After Discontinuation

Fifty-two weeks after randomization, study drug administration was discontinued. To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug.

dependent insulinotropic polypeptide hba1c
dependent insulinotropic polypeptide hba1c

After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group. At two, four, and six months after the end of study drug administration, re-elevation of HbA1c was observed in all groups. Furthermore, in the tirzepatide groups, dose-dependent ...

Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation ...

PDF Glucose dependent insulinotropic polypeptide and dipeptidyl
PDF Glucose dependent insulinotropic polypeptide and dipeptidyl

Given a similar, if not superior, effectiveness for HbA1c reduction with additional weight reduction and no intrinsic risk of hypoglycemic episodes, GLP-1RAs are recommended as the preferred first ...

Effect on Hemoglobin A1c ( HbA1c ) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist ...

Figure 1 from Effect on Hemoglobin A1c HbA1c and Body Weight After
Figure 1 from Effect on Hemoglobin A1c HbA1c and Body Weight After

Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation ...

To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug. Results After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group.

Fifty-two weeks after randomization, study drug administration was discontinued. To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug.

Improving Physicochemical Properties of Biopharmaceutical Drug
Improving Physicochemical Properties of Biopharmaceutical Drug

Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation ...

TZP effectively lowers HbA1c and induces weight loss across its three doses for type 2 diabetes management, with increased adverse events observed at higher doses.

In individuals with obesity, discontinuation resulted in substantial increases in body weight , waist circumference, body mass index (BMI), systolic blood pressure, fasting plasma glucose, and HbA1c . Similar patterns were observed in type 2 diabetes, though fasting glucose rebound was less pronounced.

Effect on Hemoglobin A1c HbA1c and Body Weight After Discontinuation
Effect on Hemoglobin A1c HbA1c and Body Weight After Discontinuation

Impact on glycated haemoglobin and body weight changes after stopping ...

The duration of the off-drug treatment period was 4 weeks, which is not enough to affect HbA1c and body weight fully or determine the long-term effects of discontinuing tirzepatide treatment.

Schematic Depiction of the Pleiotropic Benefits of Dual
Schematic Depiction of the Pleiotropic Benefits of Dual
The dual glucose dependent insulinotropic polypeptide GIP
The dual glucose dependent insulinotropic polypeptide GIP
Figure 1 from Effect on Hemoglobin A1c HbA1c and Body Weight After
Figure 1 from Effect on Hemoglobin A1c HbA1c and Body Weight After
PDF Glucose dependent insulinotropic polypeptide and glucagon like
PDF Glucose dependent insulinotropic polypeptide and glucagon like
Role of a Dual Glucose Dependent Insulinotropic Peptide GIP Glucagon
Role of a Dual Glucose Dependent Insulinotropic Peptide GIP Glucagon
Historical present and potential future PCOS therapies DPP 4
Historical present and potential future PCOS therapies DPP 4
The Road towards Triple Agonists Glucagon Like Peptide 1 Glucose
The Road towards Triple Agonists Glucagon Like Peptide 1 Glucose
Table 1 from Effect on Hemoglobin A1c HbA1c and Body Weight After
Table 1 from Effect on Hemoglobin A1c HbA1c and Body Weight After

Repeated cycles of initiation, interruption and re-initiation of these drugs might induce body weight and HbA1c fluctuations — two risk factors for cardiovascular and microvascular events.